Home/Pipeline/Amitriptyline/Gabapentin/Ketoprofen in Pentravan®

Amitriptyline/Gabapentin/Ketoprofen in Pentravan®

Chronic Neuropathic Pain

Approved/CommercialActive

Key Facts

Indication

Chronic Neuropathic Pain

Phase

Approved/Commercial

Status

Active

Company

Fagron

About Fagron

Fagron is a leading global player in pharmaceutical compounding, dedicated to widening the therapeutic scope of prescribers through innovation in personalized medicine. The company leverages its proprietary platforms like Lollibase® and Pentravan®, along with its extensive Fagron Formulary and Fagron Academy, to support the creation of patient-specific medications. With a strategic focus on compounding science, a global commercial footprint, and a commitment to ESG principles, Fagron aims to be the central hub for compounding knowledge and solutions worldwide.

View full company profile

Therapeutic Areas

Pediatrics Pain Management Dermatology Infectious Disease Neurology

Other Chronic Neuropathic Pain Drugs

Drug	Company	Phase	Status
EGFR Inhibitor (Tyrosine Kinase Inhibitor - oral)	AKIGAI	Preclinical	Active
EGFR Inhibitor (Monoclonal Antibody - parenteral)	AKIGAI	Preclinical	Active
Modified/Targeted EGFR Inhibitor	AKIGAI	Discovery	Active